ストックスクリーナーアプリを入手
11.45
18.16%
1.76
プレマーケット:
11.45
前日終値:
$9.69
開ける：
$9.93
24時間の取引高:
1.79M
Relative Volume:
2.73
時価総額：
$546.95M
収益：
-
当期純損益:
$-59.85M
株価収益率:
-12.93
EPS:
-0.8857
ネットキャッシュフロー:
$-54.54M
1週間 パフォーマンス:
+23.65%
1か月 パフォーマンス:
+74.54%
6か月 パフォーマンス:
+496.35%
1年 パフォーマンス:
+816.00%
1日の値動き範囲:
$9.93
$11.49
1週間の範囲:
$7.91
$11.49
52週間の値動き範囲:
$1.13
$11.49
Climb Bio Inc Stock (CLYM) Company Profile
Compare CLYM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
11.45 | 546.95M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | Mizuho | Outperform |
| 2026-03-24 | 開始されました | B. Riley Securities | Buy |
| 2026-03-18 | 開始されました | Truist | Buy |
| 2026-03-11 | 開始されました | Raymond James | Strong Buy |
| 2026-03-05 | 開始されました | Wedbush | Outperform |
| 2026-02-13 | 開始されました | Piper Sandler | Overweight |
| 2025-10-16 | 開始されました | William Blair | Outperform |
| 2025-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Robert W. Baird | Outperform |
| 2025-06-06 | 開始されました | Oppenheimer | Outperform |
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2024-12-02 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Climb Bio Inc (CLYM) 最新ニュース
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - Yahoo Finance
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Insider Monkey
Climb Bio reports B-cell depletion data for budoprutug trial - Investing.com UK
Climb Bio Highlights Budoprutug Progress at R&D Spotlight - TipRanks
Climb Bio : Budoprutug and the CD19 Opportunity - marketscreener.com
Climb Bio shares positive topline SC budoprutug data, ITP readout June, pMN & SLE readouts Q4 2026 - TradingView
Climb Bio (CLYM) outlines budoprutug CD19 data, 2026 trial readouts and cash runway - Stock Titan
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting - GlobeNewswire
Chardan initiates Climb Bio stock with buy on autoimmune pipeline By Investing.com - Investing.com India
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Analysts Raise Price Targets for Climb Bio Following Clinical Updates - HarianBasis.co
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026 - Insider Monkey
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
RA Capital funds receive Climb Bio (CLYM) pre-funded warrants in new grant - Stock Titan
RA Capital lifts Climb Bio (CLYM) stake with $20M PIPE warrants - Stock Titan
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease - Insider Monkey
5 Best Performing Small Cap Stocks So Far in 2026 - Insider Monkey
10 Tiny Stocks That Are On Fire Right Now - Insider Monkey
Climb Bio raises $110 million in private placement - Investing.com UK
Climb Bio raises $110 million in private placement By Investing.com - Investing.com Australia
Budoprutug potential in CD19 antibody therapy spotlighted by Climb Bio, Inc. - Traders Union
Climb Bio raises $110M in private placement; shares up - MSN
Climb Bio, Inc. announced that it expects to receive $110.076289 million in funding from a group of investors - marketscreener.com
Climb Bio Raises $110 Million in Private Placement - TipRanks
Climb Bio (CLYM) secures $110M private placement with institutional investors - Stock Titan
Climb Bio, Inc. Announces $110.0 Million Private Placement - markets.businessinsider.com
Climb Bio, Inc. Announces $110 Million Private Placement of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Institutional investors commit $110M in Climb Bio share sale - Stock Titan
Climb Bio, Inc. joins The Future of Clinical Trial Design in IgA nephropathy - Traders Union
Executive pay and governance moves at Climb Bio (NASDAQ: CLYM) - Stock Titan
Mizuho initiates coverage of Climb Bio (CLYM) with outperform recommendation - MSN
CLYM (Climb Bio Inc.) rises 3.85 percent even as fourth quarter 2025 per share earnings miss analyst estimates.Hedge Fund Inspired Picks - UBND thành phố Hải Phòng
BLTE (Belite Bio Inc American Depositary Shares) posts wider Q4 2025 loss than estimates, shares climb amid optimistic investor sentiment.Cost Structure - Xã Thanh Hà
Climb Bio, Inc. $CLYM Shares Sold by JPMorgan Chase & Co. - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Climb Bio Sees Upgraded Outlook on Strong IgAN Drug Development Pipeline, Oppenheimer Says - marketscreener.com
Oppenheimer Raises Climb Bio (NASDAQ:CLYM) Price Target to $18.00 - MarketBeat
Oppenheimer Adjusts Price Target on Climb Bio to $18 From $10, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises Climb Bio stock price target on clinical data By Investing.com - Investing.com Canada
FDA Grants Fast Track Designation to Climb Bio Kidney Drug - HarianBasis.co
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock? - Insider Monkey
8 Must-Buy Small Cap Stocks to Buy - Insider Monkey
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway (CLYM) - Seeking Alpha
Climb Bio, Inc. backs scientific collaboration on innovative trial design in nephrology - Traders Union
Climb Bio (NASDAQ:CLYM) Upgraded to "Strong-Buy" at Mizuho - MarketBeat
CLYM Initiated Coverage by Mizuho -- Rating Set to Outperform - GuruFocus
Mizuho Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $18 - Moomoo
Climb Bio Inc (CLYM) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):